España
ISCO
Me da un poco de miedo entrarle tan alto, no sé, meterme en un chicharro que acaba de duplicar su precio es mucho para mi. Tú la tienes controlada pero me da yuyu. Voy a ver como reacciona. Gracias por el aviso!!
ISCO
Y a mí. Por lo pronto, me quedo con mis 2000 acciones. Ya avisarás si ves algo. Yo mientras le sigo los fundamentales de cerca.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
ISCO
Pues de momento entre que me has avisado y ahora ya ha subido un 8% :_(
a mi me gusta xuii alto potencial tablets imerjn y mucho mas a precio ridiculo
Buenos dias,
Esto tiene mala pinta hoy, al menos aparentemente...
IBEX cayendo casi un 2%
Futuros USA en rojo, más de medio punto...
Veremos qué pasa con las farmas hoy....
Dicen que verano es bueno para el OTC, en general...
A ver si es cierto...
Parece que Argentina y el BES sirven de excusa para este varapalo...
Santander dice tener interés por el BES, si se pone a tiro y sale a cuenta...
Declaraciones de Josef Ajram en una entrevista....
Respuesta Josef Ajram. El trading funcionará siempre que haya volatilidad y volumen y en estos momentos en el mercados se están dando estas variables. Ahora mismo es más fácil ganar en bolsa con el trading que con la inversión.
Leer más: Josef Ajram: hay claras oportunidades para ganar dinero en el MAB - Bolsamania.com http://www.bolsamania.com/noticias/pulsos-europa/josef-ajram-hay-claras-oportunidades-para-ganar-dinero-en-el-mab--577059.html#QlS0IlfWptNV1S45
CONX ayer se marcó un 28%...
Ayer le dieron un premio...
A ver si hoy seguimos subiendo....
Un saludo
ISCO up +11%.....
New CHROMADEX, a ver si tiene algún efecto...
ChromaDex Signs Material Transfer Agreement With Prominent Australian Research Institute for NIAGEN™ Research
Date : 07/31/2014 @ 8:25AM
Source : PR Newswire (US)
Stock : Chromadex Inc. (QB) (CDXC)
Quote : 1.38 0.0 (0.00%) @ 8:32AM
ChromaDex Signs Material Transfer Agreement With Prominent Australian Research Institute for NIAGEN™ Research
Print
Chromadex Inc. (QB) (USOTC:CDXC)
Intraday Stock Chart
Today : Thursday 31 July 2014
Click Here for more Chromadex Inc. (QB) Charts.
IRVINE, Calif., July 31, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Murdoch Childrens Research Institute, the preeminent child health research institute in Australia. ChromaDex will provide Murdoch Childrens Research Institute with quantities of its proprietary NIAGEN™ nicotinamide riboside (NR) ingredient for research use.
ChromaDex's NIAGEN™ is the first and only commercially available form of NR, a naturally occurring vitamin B3 derivative found in milk. Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy. NAD+ is essential in supporting healthy cellular metabolism including the efficient conversation of blood glucose into energy.
Dr. David Thorburn, Mitochondrial Research group head at Murdoch Childrens Research Institute, will investigate the health benefits of NR through studies of cellular and animal models of mitochondrial respiratory chain diseases. Together with Dr. Ann Frazier and Dr. Bi-Xia Ke, and supported by a grant from the Australian Mitochondrial Disease Foundation, Dr. Thorburn will study the response to NR in mouse models with mitochondrial Complex I deficiency and in a range of human and mouse cell lines with impaired mitochondrial function.
Dr. Thorburn commented, "Mitochondrial energy generation disorders are serious conditions that vary widely in their clinical features and genetic basis. Our mouse models of Complex I deficiency show an imbalance in the NAD+/NADH ratio and NR has been shown to boost NAD levels in various model systems. We are excited to be able to study NR in a range of different pre-clinical model systems to investigate its likely utility in treating patients."
"Published research has demonstrated that nicotinamide riboside can play an important role in NAD+ production, which is an important cellular co-factor in mitochondrial health," said Frank Jaksch, Jr., founder and CEO of ChromaDex. "Researchers worldwide are working to build on this research and investigate NR's efficacy in therapeutic applications, and we are happy to support Dr. Thorburn's important research on pediatric mitochondrial disorders. Further, we're excited to add Murdoch Childrens Research Institute to our growing list of partners who are studying the science of NR."
About Nicotinamide Riboside (NR):
Sometimes referred to as the "hidden vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3). Published research has shown that NR is perhaps the most effective booster of NAD+, an essential metabolite found in all cells. NAD+ is arguably the most important cellular co-factor for the improvement of mitochondrial performance and energy metabolism. Mitochondria are the powerhouses of the cell where macronutrients are converted to energy the cell can use. Mitochondria also play an important part in the aging process. Scientists hope that the stimulation of mitochondrial function with NR may result in increased longevity as well as other health improvements. Researchers worldwide are continuing to make seminal discoveries characterizing the unique properties of NR in a wide range of health benefits. These include increased mitochondrial health, increased muscle endurance, neuroprotection, sirtuin activation, protection against weight gain on high-fat diet, protection against oxidative stress and improvement of blood glucose and insulin sensitivity.
A study by researchers from Harvard Medical School in conjunction with the National Institute on Aging published in December 2013 in Cell demonstrated that mitochondrial dysfunction (a hallmark of aging) in aging mice is due to a disruption in Sirtuin1-dependent nuclear-mitochondrial communication. The study further showed that a reduction in NAD+ levels is responsible for this disruption. Excitingly, the study demonstrated that this mitochondrial dysfunction is readily reversible by the administration of a NAD+ precursor. The study reported that, "1 week of treatment with a compound that boosts NAD+ levels is sufficient to restore the mitochondrial homeostasis and key biochemical markers of muscle health in a 22-month-old mouse to levels similar to a 6-month-old mouse," indicating that some aspects of aging may be theoretically reversible.
Separately, findings from a 2012 study conducted by researchers at Weill Cornell Medical College and the Ecole Polytechnique Federale de Lausanne, Switzerland showed that mice on a high-fat diet which were fed NR gained 60 percent less weight than mice eating the same high-fat diet without NR. Moreover, unlike the mice that were not fed NR, none of the NR-treated mice had indications that they were developing diabetes and their energy and lower cholesterol levels improved, all without side effects. The Swiss researchers were quoted as saying the effects of NR on metabolism were "nothing short of astonishing."